Bio-Techne Aktie
WKN DE: A12ENG / ISIN: US09073M1045
|
12.08.2026 13:12:53
|
Bio-Techne Posts Q4 Net Profit As Expenses Drop, Net Sales Improve
(RTTNews) - Bio-Techne Corporation (TECH), a provider of life science reagents, instruments, and services, on Wednesday reported net profit for the fourth quarter of fiscal 2026.
For the three-month period to June 30, the company posted net profit of $54.622 million, or $0.35 per share, compared with net loss of $17.677 million, or $0.11 per share in the same period last year.
Excluding items, earnings were $82.436 million, or $0.52 per share, less than $82.472 million, or $0.53 per share in the previous year.
Operating income was $74.277 million as against loss of $23.860 million a year ago.
Total operating expenses stood at $137.117 million, less than $222.672 million in the previous year. Cost of sales also moved down to $109.797 million from last year's $118.152 million.
Bio-Techne reported net sales of $321.191 million, higher than $316.964 million in the previous year.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Bio-Techne Corp
Analysen zu Bio-Techne Corp
Aktien in diesem Artikel
| Bio-Techne Corp | 62,48 | -0,19% |
|